Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

3(21%)

Results Posted

75%(3 trials)

Terminated

1(7%)

Phase Distribution

Ph early_phase_1

Ph phase_2

29%

Ph phase_4

29%

Ph phase_3

21%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution12 total trials

Early Phase 1First-in-human

1(8.3%)

Phase 2Efficacy & side effects

4(33.3%)

Phase 3Large-scale testing

3(25.0%)

Phase 4Post-market surveillance

4(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(4)

Terminated(1)

Other(5)

Detailed Status

unknown5

Completed4

Recruiting3

Terminated1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (8.3%)

Phase 24 (33.3%)

Phase 33 (25.0%)

Phase 44 (33.3%)

Trials by Status

unknown536%

recruiting321%

terminated17%

completed429%

not_yet_recruiting17%

Recent Activity

3 active trials

Showing 5 of 14

recruitingphase_4

Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women

NCT05604222

completedphase_2

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

NCT01908829

View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials

NCT05604222Phase 4

Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women

Recruiting

NCT06133075Phase 2

Using Mirabegron to Increase BP in Patients With POTS

Completed

NCT05051436Phase 4

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

Recruiting

NCT04666636Phase 2

Mechanisms for Activation of Beige Adipose Tissue in Humans

Recruiting

NCT01908829Phase 3

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

Completed

NCT06181591Phase 2

A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)

Not Yet Recruiting

NCT06124066Phase 4

THE EFFECTS OF MIRABEGRON AND TAMSULOSIN FOR PATIENTS WITH URETERAL STENTS

Completed

NCT04907032Phase 4

Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)

Completed

NCT04325880Phase 3

Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms

Unknown

NCT03411252Early Phase 1

Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study

Terminated

NCT04693897

Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker

Unknown

NCT04503850

Impact of Mirabegron on Erectile Function in BPH Patients

Unknown

NCT04286152Phase 3

Mirabegron And Ureteral Stent-related Pain (MAP) Trial

Unknown

NCT03632772Phase 2

Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP

Unknown

All 14 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 14